These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 8904046)

  • 41. New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity.
    Weislow OS; Kiser R; Fine DL; Bader J; Shoemaker RH; Boyd MR
    J Natl Cancer Inst; 1989 Apr; 81(8):577-86. PubMed ID: 2495366
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Heterogeneity of HIV-1 and HIV-2.
    Korber BT; Allen EE; Farmer AD; Myers GL
    AIDS; 1995; 9 Suppl A():S5-18. PubMed ID: 8819565
    [No Abstract]   [Full Text] [Related]  

  • 43. Potent and selective anti-HTLV-III/LAV activity of 2',3'-dideoxycytidinene, the 2',3'-unsaturated derivative of 2',3'-dideoxycytidine.
    Balzarini J; Pauwels R; Herdewijn P; De Clercq E; Cooney DA; Kang GJ; Dalal M; Johns DG; Broder S
    Biochem Biophys Res Commun; 1986 Oct; 140(2):735-42. PubMed ID: 3022729
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In-vitro activity of zidovudine, zalcitabine, and didanosine against mycoplasmas.
    Ostashewski PM; Houston SC; Robertson JA
    Lancet; 1993 Nov; 342(8881):1242-3. PubMed ID: 7901563
    [No Abstract]   [Full Text] [Related]  

  • 45. [Preliminary screening for antiviral AIDS drugs. IV. Report on fiscal year 1991].
    Kobayashi N; Noguchi Y; Matsuyama M; Akiyoshi K; Noro S; Sato N; Sakurada N; Fujita N; Ishizaki T; Kamimura N
    Eisei Shikenjo Hokoku; 1993; (111):100-2. PubMed ID: 7920545
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anomalous accumulation and decay of 2',3'-dideoxyadenosine-5'-triphosphate in human T-cell cultures exposed to the anti-HIV drug 2',3'-dideoxyinosine.
    Ahluwalia G; Cooney DA; Hartman NR; Mitsuya H; Yarchoan R; Fridland A; Broder S; Johns DG
    Drug Metab Dispos; 1993; 21(2):369-76. PubMed ID: 8097711
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Preliminary screening for antiviral AIDS drugs. IV. Report on fiscal year 1992].
    Sekine H; Ohnuki N; Sadamasu K; Ohta K; Terayama T; Kobayashi N; Noguchi Y; Matsuyama M; Akiyoshi K; Noro S
    Eisei Shikenjo Hokoku; 1994; (112):131-3. PubMed ID: 8854914
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Human red blood cells as bioreactors for the release of 2',3'-dideoxycytidine, an inhibitor of HIV infectivity.
    Magnani M; Bianchi M; Rossi L; Stocchi V
    Biochem Biophys Res Commun; 1989 Oct; 164(1):446-52. PubMed ID: 2553018
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Didanosine, a new antiretroviral drug. A review.
    Franssen RM; Meenhorst PL; Koks CH; Beijnen JH
    Pharm Weekbl Sci; 1992 Oct; 14(5):297-304. PubMed ID: 1437513
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti-HIV activity of cosalane.
    Choo V
    Lancet; 1993 Sep; 342(8873):733. PubMed ID: 8103830
    [No Abstract]   [Full Text] [Related]  

  • 51. [Various susceptibility to acriflavin in 2 strains of Herpesvirus hominis with different cytopathic effect].
    Campione-Piccardo J; Rubén Barreto M
    Rev Latinoam Microbiol; 1974; 16(4):217-26. PubMed ID: 4376255
    [No Abstract]   [Full Text] [Related]  

  • 52. In vitro and in vivo toxicity of 2',3'-dideoxycytidine in mice.
    Rossi L; Brandi G; Schiavano GF; Chiarantini L; Albano A; Magnani M
    Chem Biol Interact; 1992 Dec; 85(2-3):255-63. PubMed ID: 1337313
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Learning about HIV-2.
    O'Shaughnessy MV; Schechter MT
    Lancet; 1994 Nov; 344(8934):1380-1. PubMed ID: 7968070
    [No Abstract]   [Full Text] [Related]  

  • 54. Modified tetrazolium-based colorimetric method for determining the activities of anti-HIV compounds.
    Ayisi NK; Gupta SV; Qualtiere LF
    J Virol Methods; 1991 Aug; 33(3):335-44. PubMed ID: 1664434
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antiretroviral drug resistance in non-subtype B HIV-1, HIV-2 and SIV.
    Parkin NT; Schapiro JM
    Antivir Ther; 2004 Feb; 9(1):3-12. PubMed ID: 15040531
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Suppression of HIV production in resting lymphocytes by combining didanosine and hydroxamate compounds.
    Malley SD; Grange JM; Hamedi-Sangsari F; Vila JR
    Lancet; 1994 May; 343(8908):1292. PubMed ID: 7910296
    [No Abstract]   [Full Text] [Related]  

  • 57. Novel alkaloids from the tropical plant Ancistrocladus abbreviatus inhibit cell killing by HIV-1 and HIV-2.
    Manfredi KP; Blunt JW; Cardellina JH; McMahon JB; Pannell LL; Cragg GM; Boyd MR
    J Med Chem; 1991 Dec; 34(12):3402-5. PubMed ID: 1766007
    [No Abstract]   [Full Text] [Related]  

  • 58. HIV genetic diversity: any implications for drug resistance?
    Jülg B; Goebel FD
    Infection; 2005 Aug; 33(4):299-301. PubMed ID: 16091906
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differential cytopathicity and susceptibility of Ghanaian highly divergent HIV-2 -GH2-, prototype HIV-2 -GH1-, and prototype HIV-1 -GH3- to inhibition by ddCyd and ddIno.
    Ayisi NK
    East Afr Med J; 1995 Oct; 72(10):654-7. PubMed ID: 8904046
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.